Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITCA 650 DDI and Gastric Emptying Study
NCT02641899Phase 1Completed
- Sponsor
- Intarcia Therapeutics
- Start
- Dec 2015
- Primary completion
- Mar 2016
- Modality
- Peptides, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ITCA 650 in type 2 diabetes mellitus (T2DM), sponsored by Intarcia Therapeutics. Primary endpoints: Area under the concentration-time curve from time zero to the last measurable concentration of acetaminophen at 10 weeks, Maximum plasma concentration of acetaminophen at 10 weeks and 2 more. Started Dec 2015; status: completed.
02
Drugs
ITCA 650
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02641899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02641899.